Indoximod + Temozolomide + Cyclophosphamide + Etoposide + Lomustine
Phase 2Active 0 views this week 0 watching💤 Quiet
Interest: 39/100
39
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Glioblastoma
Conditions
Glioblastoma, Medulloblastoma, Ependymoma, Diffuse Intrinsic Pontine Glioma
Trial Timeline
Oct 2, 2019 → Oct 2, 2027
NCT ID
NCT04049669About Indoximod + Temozolomide + Cyclophosphamide + Etoposide + Lomustine
Indoximod + Temozolomide + Cyclophosphamide + Etoposide + Lomustine is a phase 2 stage product being developed by Johnson & Johnson for Glioblastoma. The current trial status is active. This product is registered under clinical trial identifier NCT04049669. Target conditions include Glioblastoma, Medulloblastoma, Ependymoma.
What happened to similar drugs?
1 of 18 similar drugs in Glioblastoma were approved
Approved (1) Terminated (1) Active (16)
Hype Score Breakdown
Clinical
12
Activity
12
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04049669 | Phase 2 | Active |
Competing Products
20 competing products in Glioblastoma